Olumiant (baricitinib) / Eli Lilly, Incyte  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Olumiant (baricitinib) / Eli Lilly
NCT04131738: Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation

Completed
1
26
US
Baricitinib, Olumiant
Washington University School of Medicine
Graft-versus-host-disease, Graft Vs Host Disease
11/21
08/22
NCT03945760: Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

Completed
1
23
US
Baricitinib, Placebo
Wright State Physicians
Allergic Contact Dermatitis
10/23
10/23
NCT06545110: Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib

Active, not recruiting
1
120
RoW
Baricitinib Oral Tablet
South Valley University
Alopecia Areata
09/24
10/24

Download Options